<DOC>
	<DOC>NCT00545714</DOC>
	<brief_summary>This single arm study will assess the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide, followed by rituximab maintenance therapy, as first line treatment of participants with CLL.</brief_summary>
	<brief_title>A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Cluster of Differentiation (CD) 20positive Bcell CLL Active disease No previous treatment Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Transformation to aggressive Bcell malignancy (prolymphocytic leukemia, largecell lymphoma, Hodgkin's lymphoma) Other malignancies except for localized skin cancer Continuous systemic corticosteroid treatment Known infection with hepatitis B or C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>